

Supplementary online material for Drugs - Real World Outcomes

Using Medicare data to assess the proarrhythmic risk of non-cardiac treatment drugs that prolong QT interval in older adults, an observational cohort study

Kin Wah Fung¹, MD, MS, MA

Fitsum Baye¹, MS

Joan Kapusnik-Uner^{2, 3}, Pharm.D

Clement J. McDonald¹, MD

Author affiliations:

¹ Lister Hill National Center for Biomedical Communications, National Library of Medicine, U.S. National Institutes of Health, Bethesda, MD, USA

² First Databank. Inc., San Francisco, CA, USA

³ University of California, San Francisco, CA, USA

Corresponding author: Kin Wah Fung

8600 Rockville Pike, Bethesda MD 20894

Email: kfung@mail.nih.gov

ORCID: 0000-0003-0593-5377

Supplementary online material

S1. Full list of QT prolonging drugs from CredibleMeds with known risk of Torsades des Pointes.

Generic Name	Drug Class	Included in study	Exclude reason
Anagrelide	Phosphodiesterase 3 inhibitor	Yes	
Azithromycin	Antibiotic	Yes	
Chlorpromazine	Antipsychotic / Antiemetic	Yes	
Cilostazol	Phosphodiesterase 3 inhibitor	Yes	
Ciprofloxacin	Antibiotic	Yes	
Citalopram	Antidepressant, SSRI	Yes	
Clarithromycin	Antibiotic	Yes	
Donepezil	Cholinesterase inhibitor	Yes	
Erythromycin	Antibiotic	Yes	
Escitalopram	Antidepressant, SSRI	Yes	
Fluconazole	Antifungal	Yes	
Haloperidol	Antipsychotic	Yes	
Hydroxychloroquine	Antimalarial, antirheumatic	Yes	
Levofloxacin	Antibiotic	Yes	
Moxifloxacin	Antibiotic	Yes	
Ondansetron	Antiemetic	Yes	
Thioridazine*	Antipsychotic	Yes	
Gatifloxacin	Antibiotic	No	Withdrawn from US market 2008**
Mesoridazine	Antipsychotic	No	Withdrawn from US market 2004
Levomethadyl acetate	Opiate	No	Withdrawn from US market 2003
Cisapride	GI stimulant	No	Withdrawn from US market 2000
Sparfloxacin	Antibiotic	No	Withdrawn from US market 2000
Astemizole	Antihistamine	No	Withdrawn from US market 1999
Grepafloxacin	Antibiotic	No	Withdrawn from US market 1999
Bepridil	Antianginal	No	Withdrawn from US market 1998
Terfenadine	Antihistamine	No	Withdrawn from US market 1997
Probucol	Antilipemic	No	Withdrawn from US market 1995
Arsenic trioxide	Anti-cancer	No	Low usage
Chloroquine	Antimalarial	No	Low usage
Cocaine	Local anesthetic	No	Low usage

Droperidol	Antipsychotic / Antiemetic	No	Low usage
Methadone	Opiate	No	Low usage
Oxaliplatin	Anti-cancer	No	Low usage
Papaverine HCl (Intra-coronary)	Vasodilator, Coronary	No	Low usage
Pentamidine	Antifungal	No	Low usage
Pimozide	Antipsychotic	No	Low usage
Propofol	Anesthetic, general	No	Low usage
Sevoflurane	Anesthetic, general	No	Low usage
Vandetanib	Anti-cancer	No	Low usage
Amiodarone	Antiarrhythmic	No	Antiarrhythmic drug
Disopyramide	Antiarrhythmic	No	Antiarrhythmic drug
Dofetilide	Antiarrhythmic	No	Antiarrhythmic drug
Dronedarone	Antiarrhythmic	No	Antiarrhythmic drug
Flecainide	Antiarrhythmic	No	Antiarrhythmic drug
Ibutilide	Antiarrhythmic	No	Antiarrhythmic drug
Procainamide	Antiarrhythmic	No	Antiarrhythmic drug
Quinidine	Antiarrhythmic	No	Antiarrhythmic drug
Sotalol	Antiarrhythmic	No	Antiarrhythmic drug

*the branded product was withdrawn worldwide in 2005, but generic versions are still available in the US

**ophthalmic form still available

S2 Days of supply of study drugs

	DAYS OF SUPPLY													
	RX	MEAN	SD	MODE	MIN	P1	P5	P10	P25	P50	P75	P95	P99	MAX
FLUOROQUINOLONE S	CIPROFLOXACIN	9	6	7	0	1	3	3	5	7	10	15	30	100
	LEVOFLOXACIN	9	5	10	0	1	3	5	7	7	10	14	30	100
	MOXIFLOXACIN	9	6	10	0	2	5	5	7	10	10	14	30	100
MACROLIDES	AZITHROMYCIN	6	6	5	0	3	3	5	5	5	5	7	30	200
	CLARITHROMYCIN	12	8	10	1	4	7	7	10	10	14	30	30	115
	ERYTHROMYCIN	15	18	10	1	1	1	1	6	10	15	30	90	100
	AMOXICILLIN	9	5	10	0	1	2	4	7	10	10	14	30	100
SSRI	CITALOPRAM	50	29	30	1	15	30	30	30	30	90	90	90	400
	ESCITALOPRAM	46	27	30	0	14	30	30	30	30	90	90	90	180
SNRI	DULOXETINE	42	25	30	0	7	30	30	30	30	30	90	90	180
	VENLAFAXINE	47	28	30	1	10	30	30	30	30	90	90	90	200
	DESVENLAFAXINE	40	23	30	1	10	30	30	30	30	30	90	90	100
	LEVOMILNACIPRAN	36	19	30	2	10	30	30	30	30	30	90	90	90
ANTIPSYCHOTIC	HALOPERIDOL	29	16	30	0	1	4	8	28	30	30	40	90	280
	CHLORPROMAZINE	27	18	30	0	2	5	7	15	30	30	90	90	100
	THIORIDAZINE	36	19	30	1	7	25	30	30	30	30	90	90	100
PDE3 INHIBITOR	CILOSTAZOL	45	26	30	1	15	30	30	30	30	60	90	90	180
	ANAGRELIDE	46	27	30	1	10	30	30	30	30	90	90	90	100
	FLUCONAZOLE	9	14	1	0	1	1	1	1	4	10	30	84	210
	ONDANSETRON	10	10	10	0	2	3	3	5	7	10	30	30	100
	HYDROXYCHLOROQUINE	50	29	30	1	15	30	30	30	30	90	90	100	200
	METHADONE	28	9	30	1	5	12	15	30	30	30	30	60	100
	DONEPEZIL	39	23	30	0	7	28	30	30	30	30	90	90	200

S3 Daily dosage of drugs – estimated by strength x quantity dispensed / days of supply (IQR – inter-quartile range)

Rx	Daily Dose, Median (IQR) in mg
Fruoroquinolone	
Ciprofloxacin	1,000.0(1,000.0-1,000.0)
Levofloxacin	500.0(500.0-500.0)
Moxifloxacin	400.0(400.0-400.0)
Macrolides	
Azithromycin	300.0(300.0-300.0)
Clarithromycin	1,000.0(1,000.0-1,000.0)
Erythromycin	1,000.0(750.0-1,562.5)
Amoxicillin	1,714.3(1,500.0-2,000.0)
SSRI	
Citalopram	20.0(20.0-40.0)
Escitalopram	10.0(10.0-20.0)
SNRI	
Duloxetine	60.0(30.0-60.0)
Venlafaxine	150.0(75.0-225.0)
Desvenlafaxine	50.0(50.0-100.0)
Levomilnacipran	40.0(40.0-80.0)
Antipsychotic	
Haloperidol	5.0(3.0-10.0)
Chlorpromazine	93.8(50.0-150.0)
Hioridazine	100.0(50.0-150.0)
Pde3 Inhibitor	
Cilostazol	200.0(100.0-200.0)
Anagrelide	10.0(5.0-15.0)
Other	
Fluconazole	150.0(100.0-150.0)
Ondansetron	16.0(12.0-24.0)
Hydrochloroquine	400.0(400.0-400.0)
Methadone	30.0(20.0-60.0)
Donepezil	10.0(5.0-10.0)

S4 Patient baseline characteristics for the short term drug analysis before and after propensity score weighting

	Unweighted Baseline Characteristics				Propensity Score Weighted Baseline Characteristics			
Baseline Characteristics	Antibacterial	Other	Combination	None	Antibacterial	Other	Combination	None
N	664,854	23,788	184,237	393,042	664,854	23,788	184,237	393,042
Age at Part D entry, Median(IQR)	65.0(65.0,65.3)	65.0(65.0,65.3)	65.0(65.0,65.2)	65.0(65.0,65.4)	65.0(65.0,65.3)	65.0(65.0,65.4)	65.0(65.0,65.3)	65.0(65.0,65.4)
Female	56.5	71.0	76.8	52.7	58.6	59.6	58.7	58.8
White	82.9	81.6	86.9	76.2	81.3	81.4	80.6	81.2
Black	6.1	8.6	5.3	9.8	7.2	7.4	7.7	7.4
Hispanic	5.0	5.0	4.2	7.0	5.5	5.4	5.6	5.5
Asian	2.7	1.5	1.4	2.9	2.5	2.5	2.6	2.5
Otehr	3.4	3.3	2.2	4.0	3.4	3.4	3.5	3.4
Ever dual	14.3	18.3	16.8	19.5	16.3	16.6	16.7	16.4
Non-dual lis	2.1	2.5	2.3	3.6	2.6	2.4	2.6	2.6
Non-dual no lis	83.6	79.3	80.9	76.9	81.1	81.0	80.7	81.0
Living in rural area	22.5	23.6	26.1	21.6	22.8	22.8	22.5	22.6
Electrolyte imbalance: hypokalemia	4.9	9.0	6.2	3.1	4.6	5.4	4.8	5.0
Bradycardia	6.2	8.6	5.9	4.0	5.6	6.4	5.8	5.8
AMI	0.8	1.0	0.7	0.6	0.7	0.8	0.7	0.8
Atrial fibrillation	3.8	4.1	3.1	2.8	3.4	3.6	3.5	3.6
Cataract	25.7	29.5	22.7	18.0	22.8	25.0	23.2	21.6
Chronic kidney disease	7.3	11.9	7.5	5.2	6.7	7.6	7.1	7.1
COPD	7.7	7.9	9.1	3.8	6.7	7.4	7.1	7.5
Heart failure	5.2	6.2	5.3	3.5	4.7	5.2	4.9	5.2
Diabetes	21.2	25.5	22.2	17.9	20.4	21.2	20.5	20.6
Glaucoma	9.4	10.1	8.0	7.5	8.6	9.0	8.7	8.3
Hip/pelvic fracture	0.3	0.6	0.3	0.2	0.3	0.3	0.3	0.3
Ischemic heart disease	18.0	17.7	16.8	12.2	16.1	16.6	16.3	16.4
Depression	12.4	19.1	15.9	8.6	11.9	12.8	12.1	12.1
Alzheimer's disease or senile dementia	1.5	2.9	1.5	1.2	1.5	1.9	1.6	1.6
Osteoporosis	5.7	7.7	6.1	3.6	5.1	5.7	5.2	4.9
Rheumatoid arthritis/osteoarthritis	21.6	26.7	23.0	11.9	18.8	20.6	19.2	18.4
Stroke/transient ischemic attack	2.6	4.1	2.6	1.9	2.4	2.8	2.6	2.6

Breast cancer	2.9	6.5	4.6	2.2	3.0	3.4	3.1	3.0
Colorectal cancer	0.8	3.1	1.4	0.7	0.9	1.1	1.0	1.0
Prostat cancer	2.3	1.8	1.4	1.8	2.0	2.2	2.0	2.0
Lung cancer	0.5	3.2	1.5	0.3	0.7	0.9	0.8	1.0
Endometrial cancer	0.3	1.6	0.6	0.3	0.4	0.5	0.4	0.4
Anemia	18.1	24.3	19.8	11.5	16.4	17.8	17.1	16.8
Asthma	4.6	4.6	5.9	2.1	4.0	4.2	4.0	4.4
Hyperlipidemia	49.8	53.1	44.2	39.8	45.8	47.7	46.1	44.8
Hyperplasia	7.6	4.8	3.8	4.2	5.9	6.2	6.0	5.9
Hypertension	50.7	56.3	48.2	42.1	47.7	49.6	48.3	47.4
Hypothyroidism	12.5	16.2	14.0	9.0	11.7	12.5	11.8	11.4
Alcohol use disorders	1.3	2.5	1.0	1.3	1.3	1.5	1.5	1.4
Anxiety disorders	6.4	11.3	7.9	4.1	6.0	6.8	6.2	6.1
Bipolar disorder	0.9	1.6	1.1	0.7	0.9	1.0	0.9	0.9
Major depressive affective disorder	7.8	12.9	9.9	5.0	7.3	8.1	7.3	7.7
Drug use disorder	0.6	1.3	0.7	0.5	0.6	0.7	0.6	0.6
Personality disorders	0.2	0.5	0.2	0.1	0.2	0.3	0.1	0.2
Schizophrenia and other psychotic disorders	0.7	1.5	0.8	0.6	0.7	0.9	0.8	0.8
Epilepsy	0.7	1.4	0.8	0.6	0.7	0.9	0.8	0.8
Cystic fibrosis and other metabolic developmental disorders	0.4	0.5	0.4	0.2	0.3	0.4	0.3	0.3
Fibromyalgia, chronic pain and fatigue	6.8	11.6	8.5	4.0	6.2	7.0	6.4	6.4
Viral hepatitis (general)	0.7	1.2	0.6	0.7	0.7	0.8	0.7	0.7
Liver disease cirrhosis and other liver conditions (excluding hepatitis)	2.5	5.6	3.1	1.7	2.4	2.9	2.6	2.6
Leukemias and lymphomas	0.8	1.7	1.5	0.5	0.8	1.0	0.9	0.9
Migraine and other chronic headache	1.4	2.6	1.9	0.8	1.3	1.5	1.3	1.3
Mobility impairments	0.8	1.7	1.0	0.7	0.8	1.0	0.9	0.9
Obesity	8.1	12.8	8.0	5.4	7.3	8.0	7.5	7.4
Overarching oud disorder	0.3	0.8	0.4	0.2	0.3	0.4	0.3	0.4
Diagonosis and procedure basis for oud	0.2	0.6	0.3	0.2	0.2	0.2	0.2	0.3
Peripheral vascular disease	4.3	5.5	4.1	2.6	3.7	4.4	3.9	4.0
Tobacco use disorders	5.5	7.9	5.6	4.0	5.1	5.7	5.5	5.5
Pressure ulcers and chronic ulcers	1.3	1.9	1.5	0.8	1.2	1.4	1.3	1.5
Sensory - deafness and hearing impairment	2.4	2.9	2.0	1.3	2.0	2.3	2.1	2.0

S5a Patient baseline characteristics for the chronic drug analysis before propensity score weighting

	Unweighted Baseline Characteristics						
Baseline Characteristics	Antidepressant	Antipsychotic	PDEI	Hydroxychloroquine	Donepezil	Combination	None
N	179,640	2,898	5,602	11,801	10,380	17,591	1,038,009
Age at Part D entry, Median(IQR)	65.0(65.0-65.2)	65.0(65.0-65.3)	65.0(65.0-65.3)	65.0(65.0-65.3)	65.0(65.0-65.8)	65.0(65.0-65.2)	65.0(65.0-65.3)
Female	74.0	37.4	41.7	78.8	55.5	70.5	55.6
White	88.8	70.2	73.6	82.0	74.3	83.6	80.2
Black	3.7	17.4	13.2	7.6	11.6	6.6	7.7
Hispanic	4.1	7.2	8.6	5.0	8.4	6.6	5.7
Asian	1.0	2.7	2.0	2.3	3.3	1.3	2.8
Other	2.5	2.5	2.5	3.0	2.4	2.0	3.6
Ever dual	17.9	45.7	31.1	12.6	33.6	33.4	15.5
Non-dual lis	2.4	2.2	3.5	2.0	2.2	2.1	2.6
Non-dual no lis	79.7	52.1	65.4	85.4	64.2	64.5	81.9
Living in rural area	24.6	23.4	25.7	23.2	24.3	25.7	22.4
Electrolyte imbalance: hypokalemia	7.9	19.6	9.6	7.1	14.0	9.5	2.7
Bradycardia	7.5	15.8	11.2	7.1	14.2	9.1	3.4
AMI	1.0	2.4	3.0	0.6	1.8	1.4	0.4
Atrial fibrillation	3.8	6.9	5.1	3.6	6.1	3.6	2.5
Cataract	24.9	26.7	26.8	28.6	39.2	24.7	14.7
Chronic kidney disease	8.8	22.9	18.5	9.0	15.9	10.4	4.1
COPD	11.0	21.5	22.5	10.2	15.9	13.4	4.4
Heart failure	6.8	14.9	15.4	6.1	12.0	8.5	3.1
Diabetes	20.3	31.9	37.5	16.9	31.8	22.8	16.3
Glaucoma	8.0	9.5	9.7	10.3	12.8	7.7	6.6
Hip/pelvic fracture	0.5	1.4	0.5	0.4	1.2	0.7	0.1
Ischemic heart disease	18.7	29.8	46.1	17.0	30.3	23.3	12.1
Depression	37.6	26.2	10.3	10.8	27.7	34.6	5.1
Alzheimer's disease or senile dementia	2.3	15.2	1.7	0.8	51.2	17.5	0.5
Osteoporosis	7.1	5.3	5.8	12.1	10.9	8.0	3.0
Rheumatoid arthritis/osteoarthritis	26.4	28.2	24.8	54.6	33.0	30.1	11.2
Stroke/transient ischemic attack	4.3	9.4	6.8	2.7	13.2	7.2	1.3
Breast cancer	4.3	2.9	1.6	3.4	3.3	3.0	2.1
Colorectal cancer	1.0	5.2	1.0	0.7	1.3	0.9	0.6

Prostat cancer	1.7	5.6	3.1	1.3	3.3	1.6	1.8
Lung cancer	1.1	8.3	1.4	0.6	1.2	0.8	0.4
Endometrial cancer	0.4	0.7	0.3	0.4	0.4	0.3	0.2
Anemia	21.9	41.1	30.9	27.2	36.5	25.8	11.0
Asthma	6.4	8.7	5.8	7.1	7.3	6.6	2.7
Hyperlipidemia	44.2	51.3	61.8	42.4	63.1	43.5	32.7
Hyperplasia	4.9	15.3	9.7	4.2	12.8	5.7	4.0
Hypertension	46.6	63.0	69.3	46.0	65.6	48.8	35.2
Hypothyroidism	14.5	13.0	11.1	17.0	17.6	13.9	7.6
Alcohol use disorders	2.0	8.1	3.5	0.9	4.1	2.7	0.7
Anxiety disorders	16.5	18.3	6.8	6.1	15.8	15.3	2.5
Bipolar disorder	1.8	8.0	0.6	0.6	3.4	3.5	0.4
Major depressive affective disorder	19.9	18.9	6.6	6.7	19.3	21.5	2.6
Drug use disorder	1.4	4.0	1.1	0.6	2.1	2.1	0.2
Personality disorders	0.4	1.6	0.1	0.1	0.7	0.7	0.1
Schizophrenia and other psychotic disorders	1.2	18.9	0.8	0.3	7.5	5.3	0.3
Epilepsy	1.0	4.2	0.9	0.7	4.1	2.0	0.4
Cystic fibrosis and other metabolic developmental disorders	0.5	0.9	0.6	0.7	0.9	0.4	0.2
Fibromyalgia, chronic pain and fatigue	13.2	15.4	9.1	15.2	12.1	13.6	3.2
Viral hepatitis (general)	0.7	2.5	1.0	0.9	1.3	0.8	0.5
Liver disease cirrhosis and other liver conditions (excluding hepatitis)	3.5	10.8	3.9	3.6	4.5	3.3	1.4
Leukemias and lymphomas	1.0	3.5	1.1	1.0	0.9	0.7	0.6
Migraine and other chronic headache	2.7	1.9	1.1	2.2	3.0	2.4	0.7
Mobility impairments	1.8	4.0	1.7	0.6	3.7	2.7	0.4
Obesity	9.8	12.1	11.1	8.7	11.2	8.1	4.1
Overarching oud disorder	0.9	2.0	0.4	0.4	0.8	1.0	0.1
Diagonosis and procedure basis for oud	0.6	1.1	0.3	0.3	0.6	0.7	0.1
Peripheral vascular disease	5.3	11.4	59.6	4.7	11.1	10.1	2.0
Tobacco use disorders	7.2	16.6	23.0	4.6	10.5	8.8	2.9
Pressure ulcers and chronic ulcers	2.0	5.9	6.8	2.1	3.6	3.4	0.7
Sensory - deafness and hearing impairment	3.0	4.5	3.0	3.4	6.0	2.9	1.2

S5b Patient baseline characteristics for the chronic use drug analysis after propensity score weighting

	Propensity Score Weighted Baseline Characteristics						
Baseline Characteristics	Antidepressant	Antipsychotic	PDEI	Hydroxychloroquine	Donepezil	Combination	None
N	179,640	2,898	5,602	11,801	10,380	17,591	1,038,009
Age at Part D entry, Median(IQR)	65.0(65.0-65.3)	65.0(65.0-65.6)	65.0(65.0-65.3)	65.0(65.0-65.2)	65.0(65.0-65.6)	65.0(65.0-65.2)	65.0(65.0-65.4)
Female	61.0	53.3	56.2	62.1	54.7	62.1	58.9
White	82.8	77.0	78.3	82.7	77.6	82.0	81.5
Black	6.5	10.4	10.8	6.9	10.1	7.4	7.2
Hispanic	5.2	6.8	5.7	4.6	6.5	5.1	5.5
Asian	2.1	2.6	2.1	2.4	2.6	2.1	2.5
Other	3.5	3.2	3.1	3.4	3.2	3.3	3.4
Ever dual	16.9	27.9	23.0	15.2	26.4	18.7	17.2
Non-dual lis	2.4	2.3	2.5	2.4	2.3	2.3	2.6
Non-dual no lis	80.8	69.8	74.5	82.4	71.2	79.0	80.2
Living in rural area	22.6	21.8	21.7	23.5	20.9	23.6	22.7
Electrolyte imbalance: hypokalemia	4.0	5.6	6.2	3.7	6.2	4.8	4.3
Bradycardia	4.2	5.2	5.6	4.2	5.8	4.6	4.6
AMI	0.5	0.7	1.1	0.5	1.1	0.6	0.6
Atrial fibrillation	2.7	3.8	2.9	2.4	3.7	2.6	2.9
Cataract	15.5	16.6	15.7	15.3	17.3	15.5	16.3
Chronic kidney disease	5.4	8.3	9.5	5.3	7.7	5.9	5.6
COPD	6.2	7.7	9.4	5.6	8.1	7.2	6.4
Heart failure	4.2	5.4	7.5	3.7	6.4	5.2	4.4
Diabetes	17.0	19.4	20.5	14.3	19.1	17.3	17.4
Glaucoma	6.2	5.6	5.9	6.2	5.8	5.9	6.8
Hip/pelvic fracture	0.2	0.4	0.5	0.2	0.5	0.3	0.3
Ischemic heart disease	13.5	16.7	19.9	12.4	15.9	14.5	14.1
Depression	11.6	14.1	12.5	9.7	15.1	12.1	11.9
Alzheimer's disease or senile dementia	1.6	3.6	1.8	1.3	1.7	2.0	2.3
Osteoporosis	3.7	3.0	3.9	3.6	4.2	4.1	3.9
Rheumatoid arthritis/osteoarthritis	14.2	15.3	14.9	16.3	15.9	15.8	14.6
Stroke/transient ischemic attack	2.1	3.6	3.7	1.9	5.2	2.9	2.4
Breast cancer	2.5	2.1	2.8	2.2	2.1	2.2	2.4
Colorectal cancer	0.7	1.0	0.8	0.6	0.8	0.7	0.7

Prostat cancer	1.6	2.2	1.3	1.6	1.7	1.3	1.8
Lung cancer	0.6	1.1	0.9	0.6	0.7	0.8	0.6
Endometrial cancer	0.3	0.3	0.5	0.4	0.3	0.5	0.3
Anemia	13.6	16.9	20.2	13.3	17.5	14.8	14.0
Asthma	3.5	4.8	4.0	3.3	3.8	3.8	3.6
Hyperlipidemia	33.3	34.3	32.9	31.6	36.4	31.6	35.0
Hyperplasia	3.8	5.5	4.5	4.2	5.3	3.6	4.3
Hypertension	36.1	40.1	39.8	35.1	40.3	35.3	37.9
Hypothyroidism	8.9	7.9	9.9	9.3	9.7	8.5	9.0
Alcohol use disorders	1.1	1.7	0.9	1.0	2.4	1.3	1.1
Anxiety disorders	6.0	7.4	7.0	5.2	7.4	5.9	6.1
Bipolar disorder	1.0	2.5	0.8	0.6	2.0	0.9	0.9
Major depressive affective disorder	6.0	8.4	7.4	6.0	9.6	7.0	7.1
Drug use disorder	0.6	0.8	1.0	0.7	1.2	0.7	0.6
Personality disorders	0.2	0.4	0.4	0.2	0.3	0.2	0.2
Schizophrenia and other psychotic disorders	0.8	1.8	1.4	0.6	2.1	1.1	1.0
Epilepsy	0.6	1.3	0.5	0.6	1.6	0.8	0.7
Cystic fibrosis and other metabolic developmental disorders	0.3	0.4	0.1	0.2	0.5	0.2	0.2
Fibromyalgia, chronic pain and fatigue	5.3	5.5	6.4	6.8	6.2	5.9	5.6
Viral hepatitis (general)	0.5	1.3	0.5	0.5	0.8	0.5	0.6
Liver disease cirrhosis and other liver conditions (excluding hepatitis)	1.9	3.3	1.9	1.8	3.1	2.0	2.0
Leukemias and lymphomas	0.7	1.1	1.0	0.6	0.8	0.6	0.7
Migraine and other chronic headache	1.1	1.7	0.9	1.1	1.4	1.1	1.2
Mobility impairments	0.8	2.1	1.6	0.7	2.5	1.4	1.0
Obesity	5.2	5.2	6.3	5.2	6.3	5.3	5.3
Overarching oud disorder	0.3	0.7	0.6	0.4	0.6	0.4	0.4
Diagonosis and procedure basis for oud	0.2	0.4	0.4	0.4	0.4	0.3	0.3
Peripheral vascular disease	3.1	4.5	3.5	3.1	5.3	4.7	3.4
Tobacco use disorders	4.0	6.5	5.3	3.9	5.3	4.7	4.3
Pressure ulcers and chronic ulcers	1.1	1.5	2.5	0.8	2.5	1.7	1.3
Sensory - deafness and hearing impairment	1.5	1.4	1.9	1.7	2.1	1.4	1.6